Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Share your pick for the tree that you love for its novel magnificence! - 2Overlooked infertility care should be part of national health services, says WHO
- 36 Agreeable Earphones To Wear
- 4California warns of death cap mushrooms outbreak resulting in 3 deaths
- 5Kiev declares energy emergency after Russian attacks amid winter cold
- ChatGPT served as "suicide coach" in man's death, lawsuit alleges
- No red, no long shorts: The fashion rules Joe Burrows lives by
- Which Diet Prompts the Incomparable Wellbeing Results?
- RFK Jr. wants to scrutinize the vaccine schedule – but its safety record is already decades long
- Cyber Monday 2025: Save over 70% on HBO Max with this Prime Video streaming deal
- ‘More should be done’: UN pushes Syrian regime on justice for Druze, Alawites and minority groups
- 6 Tire Brands Reasonable for Seniors
- The Delight of Perusing: Book Proposals for Each Class
- New peace laureate: Iran's arrest of Mohammadi 'confession of fear'
